Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 4, 2021Andrew Drechsler to Retire as Chief Financial Officer in December
-
Oct 26, 2021PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers
-
Oct 25, 2021Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
-
Oct 22, 2021Pivotal trial met primary and all key secondary endpoints
-
Oct 20, 2021Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
-
Oct 7, 2021First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
-
Sep 28, 2021Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza
-
Sep 19, 2021*Phase 3 trial met its primary and key secondary endpoints
-
Sep 13, 2021Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy
-
Aug 30, 2021Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
-
Aug 6, 2021Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile
-
Aug 5, 2021Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death
-
Jul 29, 2021Fifth disease that Dupixent has demonstrated positive pivotal results
-
Jul 12, 2021Designation is the first step in a new MHRA initiative to accelerate the development and access to innovative medicines in the UK post-Brexit
-
Jul 6, 2021Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstanding
-
Jul 2, 2021New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented
-
Jun 28, 2021* Study also shows more people on Soliqua 100/33 had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin
-
Jun 28, 2021- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2
-
Jun 17, 2021* $425 million investment in Sanofi's Swiftwater, PA facility expands production of Fluzone® High-Dose Quadrivalent for people 65 and older in the U.S.
-
Jun 11, 2021Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful
-
Jun 4, 2021* Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research
-
Jun 1, 2021* This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
May 27, 2021If approved, teplizumab will be the first disease-modifying therapy in T1D
-
May 27, 2021-- FDA Advisory Committee to Review Biologics License Application for PRV-031 for the Delay of Clinical Type 1 Diabetes --
-
May 19, 2021Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer
-
May 19, 2021- Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib
-
May 17, 2021- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients
-
May 12, 2021Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy
-
May 6, 2021Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research* Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions
-
Apr 26, 2021- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic
-
Apr 26, 2021Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1-5
-
Apr 23, 2021Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis
-
Apr 8, 2021- Conference call and webcast to be held today at 5:00 p.m. Eastern Time -
-
Apr 7, 2021Data from the pivotal Phase 3 CARDINAL study demonstrated sutimlimab inhibited C1-activated hemolysis (abnormal destruction of healthy red blood cells) within one week of treatment and had a sustained treatment effect over the course of the study
-
Apr 7, 2021* Launch of a new and more impactful global corporate social responsibility strategy